Brenu, Ekua W <br/><br/>
CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.  [electronic resource] 

 -  Immunology and cell biology  10 2017 
 - 803-813 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1440-1711 
<br/><br/><label>Standard No.: </label>10.1038/icb.2017.49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Blocking--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>CD11a Antigen--immunology<br/>Cell Proliferation<br/>Cytotoxicity, Immunologic<br/>Diabetes Mellitus, Type 1--immunology<br/>Humans<br/>Immunotherapy--methods<br/>Insulin-Secreting Cells--immunology<br/>Intercellular Adhesion Molecule-1--immunology<br/>Interleukin-2--immunology<br/>Killer Cells, Natural--immunology<br/>Lymphocyte Activation<br/>Mice<br/>Mice, Inbred NOD<br/>T-Lymphocyte Subsets--immunology<br/>T-Lymphocytes, Regulatory--immunology